Spots Global Cancer Trial Database for conversion therapy
Every month we try and update this database with for conversion therapy cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | NCT05988372 | Locally Advance... | Surufatinib + S... Albumin-paclita... | 18 Years - 75 Years | Sun Yat-sen University | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC | NCT05056337 | Hepatocellular ... | Lenvatinib 4 MG... Toripalimab TACE | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA | NCT03679039 | Colorectal Canc... | 18 Years - | Fudan University | ||
| Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | NCT04263870 | Gastroesophagea... Stomach Adenoca... Locally Advance... Metastatic Gast... | sintilimab | 18 Years - 75 Years | Sichuan University | |
| Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer | NCT05228743 | Gastric Cancer | Comparing Hyper... Paclitaxel S1 | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC | NCT04967482 | Hepatocellular ... | Drug-eluting be... Conventional tr... | 18 Years - 70 Years | Second Affiliated Hospital of Guangzhou Medical University | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC | NCT04945928 | Pulmonary Neopl... Advanced Cancer Locally Advance... | Surgery | 18 Years - | Ruijin Hospital | |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | NCT04267549 | Gastric Cancer ... | sintilimab apatinib S1 Nab paclitaxel | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer | NCT05385809 | Unresectable Ga... | 18 Years - 75 Years | Zhejiang Cancer Hospital | ||
| Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE) | NCT05988372 | Locally Advance... | Surufatinib + S... Albumin-paclita... | 18 Years - 75 Years | Sun Yat-sen University | |
| The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | NCT04694183 | Stomach Neoplas... | Camrelizumab S-1 Oxaliplatin Paclitaxel | 18 Years - 75 Years | The First Hospital of Jilin University | |
| Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC | NCT05394415 | Esophageal Squa... Tislelizumab Chemoradiation | Tislelizumab Paclitaxel Carboplatin Radiotherapy | 18 Years - 75 Years | Jiangsu Cancer Institute & Hospital | |
| A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma | NCT05099848 | Hepatocellular ... | Camrelizumab | 18 Years - 80 Years | Shandong Cancer Hospital and Institute | |
| Conversion From Unresectable To Resectable Metastatic Colorectal Cancer. | NCT03401294 | Metastatic Colo... | FOLFOXIRI and B... | 18 Years - 70 Years | University of Saskatchewan | |
| FOLFOXIRI With or Without Cetuximab as First-line Treatment of Patients With Non-resectable Liver - Only Metastatic Colorectal Cancer | NCT02063529 | Metastatic Colo... | FOLFOXIRI + Cet... FOLFOXIRI | 18 Years - 65 Years | Sun Yat-sen University | |
| Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer | NCT05228743 | Gastric Cancer | Comparing Hyper... Paclitaxel S1 | 18 Years - 70 Years | Tianjin Medical University Cancer Institute and Hospital | |
| The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | NCT04694183 | Stomach Neoplas... | Camrelizumab S-1 Oxaliplatin Paclitaxel | 18 Years - 75 Years | The First Hospital of Jilin University | |
| FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type | NCT02350530 | Metastatic Colo... | FOLFOXIRI + Bev... FOLFOXIRI | 18 Years - 70 Years | Sun Yat-sen University | |
| Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma | NCT06405321 | Hepatocellular ... | Conversion or n... | 18 Years - 75 Years | Guangxi Medical University | |
| Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer | NCT04267549 | Gastric Cancer ... | sintilimab apatinib S1 Nab paclitaxel | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine as Conversion Therapy of Locally Advanced Colorectal Cancer | NCT06405139 | Colorectal Canc... | Nanoliposomal I... | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma | NCT05821452 | Chemotherapy Radiation Thera... | Camrelizumab Paclitaxel Cisplatin Radiotherapy | 18 Years - 75 Years | Fujian Medical University Union Hospital | |
| A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA | NCT03679039 | Colorectal Canc... | 18 Years - | Fudan University | ||
| Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma | NCT04047953 | Gastric Adenoca... | Paclitaxel (alb... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
